CN111544470A - Traditional Chinese medicine composition for treating heart failure - Google Patents
Traditional Chinese medicine composition for treating heart failure Download PDFInfo
- Publication number
- CN111544470A CN111544470A CN202010464299.1A CN202010464299A CN111544470A CN 111544470 A CN111544470 A CN 111544470A CN 202010464299 A CN202010464299 A CN 202010464299A CN 111544470 A CN111544470 A CN 111544470A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart failure
- traditional chinese
- chinese medicine
- treating heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 7
- 240000005748 Achyranthes aspera Species 0.000 claims abstract description 6
- 235000005517 Achyranthes aspera Nutrition 0.000 claims abstract description 6
- 241000893536 Epimedium Species 0.000 claims abstract description 6
- 241000028204 Vincetoxicum atratum Species 0.000 claims abstract description 6
- 235000018905 epimedium Nutrition 0.000 claims abstract description 6
- 241001116477 Adenophora triphylla Species 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims abstract description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 3
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 3
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 3
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 5
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 240000007371 Cuscuta campestris Species 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 241000219304 Portulacaceae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- -1 resveratrol glucoside Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229930182836 (R)-noradrenaline Natural products 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating heart failure, which is prepared from the following raw materials in parts by weight: 4.5-9 parts of cynanchum atratum and epimedium; semen cuscutae, polygonum cuspidatum, purslane and adenophora tetraphylla 9-18 parts; 15-30 parts of achyranthes aspera. The invention has the characteristics of obvious treatment effect, short treatment period, no toxic or side effect and the like.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating heart failure.
Background
Heart failure is a complex clinical syndrome of cardiac insufficiency caused by various heart diseases, and is a disease in which the ventricular blood pumping capability is reduced, the cardiac output is reduced, and the metabolic needs of the organism cannot be met.
Patients with heart failure easily relapse, western medicines have poor treatment effects, some patients are easy to be poisoned by digoxin when taking the medicine, easy to have cough when taking ACEI, easy to have low potassium and low sodium when using diuretics and have serious side effects, or patients with contraindications and cautions on western medicines, such as slow heart rate and the like.
Disclosure of Invention
The invention aims to improve the defects of the prior art and provides a traditional Chinese medicine composition for treating heart failure, which has the characteristics of obvious treatment effect, short treatment period, no toxic or side effect and the like.
The term "heart failure" was originally found in "holy-economical general records" and "hearts" of the Song Dynasty: amnesia due to heart failure, pain in chest, abdomen, hypochondrium, waist and back due to deficiency, palpitation, absentmindedness, little color, and strong tongue. The description of "heart failure" was first found in the "internal classic: "distention in the heart, restlessness, heart impediment, obstructed pulse, restlessness leading to lower heart bulge, upper qi and dyspnea". Heart failure is usually seen in the clinical manifestations of palpitation, severe palpitation, asthma, edema, phlegm and fluid retention, etc.
The traditional Chinese medicine considers that in the early stage of the disease, phlegm, blood stasis and water and yin are exuberant, and yang qi is not deficient; in the middle stage of the disease, yang deficiency is accompanied by turbid phlegm and water; in the late stage of the disease, yang impairment affects yin and yang are both deficient.
For heart failure, it is necessary to warm and nourish yin of heart, lung and kidney, stimulate yang qi, nourish qi of lung and spleen, nourish yin to support yang, and balance yin, yang, qi and blood of whole body.
Based on the theory, the technical scheme of the invention is as follows: an oral traditional Chinese medicine for treating heart failure comprises the following raw material medicines in parts by weight: 4.5-9 parts of cynanchum atratum and epimedium; semen cuscutae, polygonum cuspidatum, purslane and adenophora tetraphylla 9-18 parts; 15-30 parts of achyranthes aspera;
in a preferred embodiment, the traditional Chinese medicine composition for treating heart failure is composed of the following raw material medicines in parts by weight: 9 parts of cynanchum atratum and epimedium; dodder seed, giant knotweed rhizome, purslane, adenophora tetraphylla 18 parts; 30 parts of achyranthes aspera;
among them, giant knotweed rhizome is slightly bitter and cold. It enters liver, gallbladder and lung meridians. Promoting blood circulation and removing blood stasis; dispelling wind and dredging collaterals; clearing heat and promoting diuresis; detoxify and relieve pain, relieve cough and resolve phlegm.
Giant knotweed rhizome has obvious functions of lowering blood pressure and slowing down heart rate. The giant knotweed rhizome has obvious effects of inhibiting platelet aggregation, improving microcirculation, exciting myocyte, having obvious positive inotropic effect on heart and resisting heart failure. The contained resveratrol glucoside (PD) has protective effect on glucose deficiency, anoxia and injured myocardial cells.
Radix cynanchi atrati: bitter, salty and cold. It enters stomach, liver and kidney meridians. Clearing away heat, nourishing yin, inducing diuresis, treating stranguria, removing toxic substance, and treating sore. Cynanchum atratum can directly enhance myocardial contraction and slow heart rate, and can be used for treating congestive heart failure.
Herba epimedii: pungent, sweet and warm. It enters liver and kidney meridians. Tonify kidney yang, strengthen tendons and bones, dispel wind-damp. The epimedium herb can obviously increase the coronary flow of the heart to ensure that the coronary flow is averagely increased by 126.6 percent, can obviously reduce the coronary resistance, obviously increase the myocardial tension, obviously enhance the myocardial contractility and can recover the myocardial tension of patients with heart failure. Herba Epimedii has effects of lowering blood pressure, protecting acute myocardial ischemia, and slowing down heart rate.
Achyranthes aspera: slightly bitter in flavor and cool. Promoting blood circulation and removing blood stasis; purging pathogenic fire and removing toxic substances; induce diuresis to treat stranguria. Tu niu xi can obviously strengthen the contractility of heart. When the heart is in failure, it can be placed in increased tension.
Dodder seed: sweet and warm. It enters liver, kidney and spleen meridians. Tonifying kidney and replenishing vital essence; nourishing liver and improving eyesight; secure essence and reduce urination, prevent abortion, improve eyesight and check diarrhea. Semen Cuscutae extract has effect in tonifying heart.
Radix adenophorae: sweet and slightly cold. It enters lung and stomach meridians. To nourish yin and clear lung-heat, resolve phlegm and tonify qi.
Radix Adenophorae has obvious cardiotonic effect, and can increase cardiac amplitude by more than 50%.
Purslane: sour and cold in flavor. Clear heat and promote diuresis, activate blood and relieve swelling, cool blood and remove toxicity. Herba Portulacae contains abundant L-norepinephrine, and can stimulate blood vessel B-receptor, increase coronary blood flow, and enhance myocardial contractility and heart autorhythm. The purslane contains rich omega-3 fatty acid, can inhibit the generation of cholesterol and triglyceride, and has good effect on reducing the occurrence of cardiovascular diseases.
The Chinese medicinal composition for treating the heart failure is prepared from Chinese traditional Chinese medicinal herbs, and is prepared from certain natural extracts with definite components and clear effects according to a plurality of principles of traditional Chinese medicine treatment based on syndrome differentiation and modern medicine.
The traditional Chinese medicine composition has the efficacy of heart failure, can enhance the immune function of organisms, can effectively treat and the like, is safe, reliable, free of obvious toxic and side effects, free of damage to spleen and stomach, convenient for patients to insist on taking for a long time, can treat both symptoms and root causes, and is not easy to relapse.
The traditional Chinese medicine composition has the advantages of small number of medicines, easily obtained raw materials, simple process, low cost and high efficiency, and is beneficial to pharmaceutical enterprises to carry out medicine production and quality control; the product has low price and is easy to be accepted by patients.
The traditional Chinese medicine composition has a remarkable effect on treating heart failure, and clinical experiment results show that the traditional Chinese medicine composition is used for treating heart failure, one dose of the traditional Chinese medicine composition is taken every day, the traditional Chinese medicine composition is decocted with 100 ml of water for 150ml and divided into two parts, one part is taken in the morning and at night, one month is a treatment course, the cure rate is 56% in 5-6 treatment courses, the close control and significant efficiency is 94%, the total effective rate is 100%, and the symptoms of patients after treatment in a treatment group are remarkably improved.
The treatment cost of the invention is relatively low and is far lower than that of western medicine.
The invention also provides an oral preparation prepared from the traditional Chinese medicine composition for treating heart failure, which comprises oral liquid, tablets, capsules, pills and the like, preferably the dosage forms are tablets and capsules, and one dose is taken every day in the morning and at night.
The traditional Chinese medicine composition can be prepared into various dosage forms. For example, the decocted liquid medicine is sterilized and disinfected and then packaged to prepare oral liquid; or concentrating the decoction, oven drying, adding pharmaceutically acceptable adjuvants, and making into tablet, capsule, pill, etc.
The medically acceptable auxiliary materials comprise starch, dextrin, sodium carboxymethylcellulose, polyethylene glycol, calcium hydrophosphate, sodium alginate, potassium sorbate and the like.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention in any way, and it will be apparent to those skilled in the art that the above description of the present invention can be applied to various modifications, equivalent variations or modifications without departing from the spirit and scope of the present invention.
Claims (4)
1. A traditional Chinese medicine composition for treating heart failure is characterized by comprising the following components: 4.5-9 parts of cynanchum atratum and epimedium; semen cuscutae, polygonum cuspidatum, purslane and adenophora tetraphylla 9-18 parts; 15-30 parts of achyranthes aspera.
2. The traditional Chinese medicine for treating heart failure according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 9 parts of cynanchum atratum and epimedium; dodder seed, giant knotweed rhizome, purslane, adenophora tetraphylla 18 parts; 30 parts of achyranthes aspera.
3. An oral preparation for treating heart failure, which is prepared from the Chinese medicinal composition of any one of claims 1 or 2.
4. The oral preparation for treating heart failure according to claim 3, which is characterized by comprising oral liquid, tablets, capsules and pills, preferably capsules and tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464299.1A CN111544470A (en) | 2020-05-28 | 2020-05-28 | Traditional Chinese medicine composition for treating heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464299.1A CN111544470A (en) | 2020-05-28 | 2020-05-28 | Traditional Chinese medicine composition for treating heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111544470A true CN111544470A (en) | 2020-08-18 |
Family
ID=72006742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464299.1A Pending CN111544470A (en) | 2020-05-28 | 2020-05-28 | Traditional Chinese medicine composition for treating heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544470A (en) |
-
2020
- 2020-05-28 CN CN202010464299.1A patent/CN111544470A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN102210839A (en) | Traditional Chinese medicine capsule for treating coronary heart disease | |
| CN111544470A (en) | Traditional Chinese medicine composition for treating heart failure | |
| CN113181258A (en) | A Chinese medicinal composition for treating menoxenia, dysmenorrhea, and amenorrhea | |
| CN113144076A (en) | Traditional Chinese medicine composition for treating myocarditis | |
| CN100386111C (en) | Recovery mixture for liver, gallbladder and stomach and its preparing method | |
| CN105396017A (en) | Traditional Chinese medicine preparation used for treating fatty liver, and preparation method thereof | |
| CN111529579A (en) | A Chinese medicinal composition for relieving hangover and treating alcoholic liver | |
| CN111529576A (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN109078157A (en) | A kind of anti-tumor drug and preparation method thereof | |
| CN104524461A (en) | Medicine composition for treating myocarditis and application thereof | |
| CN104352954A (en) | Compound traditional Chinese medicine formula resisting helicobacter pylori | |
| CN107854685A (en) | A kind of Chinese medicine composition with antitumor action and its production and use | |
| CN107669910A (en) | Treat the pharmaceutical composition of atherosclerosis | |
| CN100571739C (en) | Herbal mixture of treatment cardiovascular disease and preparation method thereof | |
| CN111714601A (en) | A Chinese medicinal composition for treating fungal infection | |
| CN105853851A (en) | Powder for treating heart failure by warming yang and tonifying qi | |
| CN116019878A (en) | Chinese medicine effective part composition for treating diabetes | |
| CN111658697A (en) | Traditional Chinese medicine composition for treating chronic enteritis | |
| CN116115705A (en) | Traditional Chinese medicine composition for treating myocardial infarction | |
| CN103800595A (en) | Traditional Chinese medicine for treating cysticercus cellulosae | |
| CN111494528A (en) | Traditional Chinese medicine composition for treating pulmonary heart disease | |
| CN108295184A (en) | Traditional Chinese medicine formula for treating gastric ulcer | |
| CN108635543A (en) | Treat the drug and preparation method thereof of the proliferation of mammary gland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200818 |